Venoactive Drug Treatment of Pelvic Venous Disorders

PHASE3RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

February 28, 2025

Conditions
Pelvic Venous Disorders
Interventions
DRUG

Micronized purified flavonoid fraction

"Micronized purified flavonoid fraction (MPFF) 1000. Active substance: micronized purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin). MPFF is a venotonic agent that also has angioprotective properties. It reduces venous distensibility and blood stasis, capillary permeability, and increases capillary resistance.~MOFF 1000 dosing regimen is 1000 mg once daily for 2 months."

DRUG

Diosmin 600

Venotonic action: the drug reduces venous distensibility, increases venous tone, reduces blood stasis, and enhances the vasoconstrictor effect of epinephrine and norepinephrine. The optimal daily dose of diosmin 600 for obtaining venotonic effect is 600 mg.

DRUG

Hesperidin+Diosmin combination 1000

"A venotonic agent that also has angioprotective properties. It reduces venous distensibility and blood stasis, reduces capillary permeability and increases their resistance.~Hesperidin+Diosmin combination 1000 dosing regimen is 1000 mg once daily for 2 months"

Trial Locations (1)

117513

RECRUITING

Pirogov Russian National Research Medical University, Moskva

All Listed Sponsors
lead

Pirogov Russian National Research Medical University

OTHER